Desmopressin duration of antidiuretic action in patients with central diabetes insipidus
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The key question answered by this study is whether it is possible to deliver a pharmacokinetic and pharmacodynamic duration of antidiuretic action long enough to ensure adequate antidiuresis with two daily administrations of desmopressin in patients with central diabetes insipidus (CDI). We studied the efficacy and safety of desmopressin i.v. in 13 CDI patients using two 3-way crossover designs, in the doses 30, 60, 125 ng, and 125, 250 and 500 ng. Duration of action, minimum output rate, max osmolality and average osmolality during action (AUC osmolality) were measured every 30 min for the first 2 h during the infusion, and then every hour or every second hour until the urine output rate was greater than 2 ml/kg/30 min. The duration of antidiuretic action was 4, 8 and 11 h, respectively, for 125, 250, and 500 ng, increasing from 250 to 500 ng but for the remaining secondary dynamic efficacy parameters no difference could be detected based on descriptive statistics between the doses 250 and 500 ng, indicating that the upper plateau region of the dose-response curve had been reached. All treatment emergent adverse events were classified as unrelated or unlikely related to trial medication. No serious adverse events occurred. Data on duration of action indicates that it is possible to achieve antidiuretic control with 500 ng i.v. corresponding to 160 μg orodispersible tablets twice daily in CDI patients. Today, the Minirin Melt label recommends the majority of CDI patients a do…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral and sublingual DDAVP absorption rates are <1%, while intranasal is ~6% (180).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [180]
In the citing paper
“With parenteral administration of desmopressin, the usual duration of action is 12 h [71]; however, significant inter-individual variability occurs in the duration and the amplitude of the effect [72]”
From Diabetes Insipidus after Traumatic Brain Injury (2015) · cites this paper as [72]
Citations
Cites
Desmopressin 30 Years in Clinical Use: A Safety Review
Vande Walle, J., Stockner, M., Raes, A., & Norgaard, J. (2007) · Current Drug Safety · doi:10.2174/157488607781668891 · Cited by 172 · cited 1×
“Due to the antidiuretic effect of desmopressin, there is a well-known risk of developing hyponatraemia during desmopressin treatment [ 14 ].”
BackgroundSelf-citationDDAVP in the Treatment of Central Diabetes Insipidus
Robinson, A. G. (1976) · New England Journal of Medicine · doi:10.1056/nejm197603042941001 · Cited by 163
Vasopressin Analogue DDAVP in Diabetes Insipidus: Clinical and Laboratory Studies
Edwards, C. R. W., Kitau, M. J., Chard, T., & Besser, G. M. (1973) · BMJ · doi:10.1136/bmj.3.5876.375 · Cited by 137
Gender difference in antidiuretic response to desmopressin
Juul, K. V., Klein, B. M., Sandström, R., Erichsen, L., & Nørgaard, J. P. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00741.2010 · Cited by 128
Self-citationEFFECTS OF DDAVP, A SYNTHETIC ANALOGUE OF VASOPRESSIN, IN PATIENTS WITH CRANIAL DIABETES INSIPIDUS
Andersson, K., & ARNER, B. (1972) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1972.tb04772.x · Cited by 111
Walle, J. V., Bogaert, G., Mattsson, S., Schurmans, T., Hoebeke, P. B., DEBOE, V., Nørgaard, J. P., & the ‘Desmopressin oral lyophilisate PD/PK study group’ (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.05999.x · Cited by 79
Self-citationLAM, K. S. L., WAT, M. S., CHOI, K. L., IP, T. P., PANG, R. W. C., & KUMANA, C. R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.39914.x · Cited by 58 · cited 1×
“The pharmacodynamic and -kinetic evidence on desmopressin antidiuretic duration of action in the early CDI studies that followed the introduction of desmopressin in the 1970s [2, 4‐9] was based initially on nasal and later on oral formulations that both are subject to large intra-patient variations in pharmacokinetics…”
BackgroundØsterberg, O., Savic, R. M., Karlsson, M. O., Simonsson, U. S. H., Nørgaard, J. P., Walle, J. V., & Agersø, H. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291838 · Cited by 54 · cited 4×
“A one compartment model with first-order elimination was determined as the most optimal model for the description of the plasma concentration time profile in accordance with other desmopressin PK-studies [ 10 ].”
BackgroundMethodResultInfluentialSelf-citationFUKUDA, I., HIZUKA, N., & TAKANO, K. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.437 · Cited by 38
Oral desmopressin in central diabetes insipidus.
Westgren, U., Wittstrom, C., & Harris, A. S. (1986) · Archives of Disease in Childhood · doi:10.1136/adc.61.3.247 · Cited by 36 · cited 1×
“dosing [ 2 ], and for the majority of patients, the maintenance dose is recommended as 60 to 120 lg sublingually three times daily according to the current label and SmPC [3].”
Background
Research works printed but not linked: 2
- H. Vilhardt, Expert Report Oral dDAVP in Diabetes Insipidus and Nocturnal Enuresis (University of Copenhagen, Denmark, 1993)
- R.W. Schrier, in Section XI: Disorders of electrolyte, water, and acid-base. Diseases of the Kidney and Urinary Tract (Lippincott Williams & Wilkins, 2007), p. 2223
Cited by
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Diagnosis and Management of Central Diabetes Insipidus in Adults
Tomkins, M., Lawless, S., Martin-Grace, J., Sherlock, M., & Thompson, C. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac381 · Cited by 159
Diabetes Insipidus after Traumatic Brain Injury
Capatina, C., Paluzzi, A., Mitchell, R., & Karavitaki, N. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4071448 · Cited by 120
“inter-individual variability occurs in the duration and the amplitude of the effect [72] and treatment with additional doses should be dictated by careful assessment of the fluid and electrolyte balance.”
BackgroundTreatment of Neurohypophyseal Diabetes Insipidus
Oiso, Y., Robertson, G. L., Nørgaard, J. P., & Juul, K. V. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2326 · Cited by 101
Self-citationArima, H., Oiso, Y., Juul, K. V., & Nørgaard, J. P. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0165 · Cited by 39
Self-citation
Metadata
- Authors
- Juul, K. V., Bichet, D. G., & Nørgaard, J. P.
- Affiliations
- Ferring Pharmaceuticals (Denmark) (DK)
- Hôpital du Sacré-Cœur de Montréal (CA)
- Lund University (SE)
- Corresponding author
- Juul, Kristian Vinter
- Venue
- Endocrine
- Published
- 2011-05-29
- Volume
- 40
- Issue
- 1
- Pages
- 67-74
- ISSN
- 0969-711X (ISSN-L)
- 1355-008X
- 1559-0100
- OpenAlex
- W2160190817
- Cited by
- 26
- References
- 11
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2019: 3 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 3
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Endocrine (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- desmopressin, central diabetes insipidus, intravenous administration, dose-response relationship, osmolality, urine output, orally disintegrating tablets, treatment-emergent adverse events
- MeSH terms
- Administration, Oral, Adult, Deamino Arginine Vasopressin, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Osmolar Concentration, Sodium, Thirst, Time Factors, Urine, Treatment Outcome, Cross-Over Studies, Diabetes Insipidus, Neurogenic, Antidiuretic Agents, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. https://app.cochat.ai/papers/10.1007/s12020-011-9492-z
- The paper
- Juul, K. V., Bichet, D. G., & Nørgaard, J. P. (2011). Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. https://doi.org/10.1007/s12020-011-9492-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.